1354910-18-1

Basic information

• Product Name: tert-butyl 2-(4-hydroxyphenyl)-6,7-dihydrooxazolo[4,5-c]pyridine-5(4H)-carboxylate
• Synonyms: tert-butyl 2-(4-hydroxyphenyl)-6,7-dihydrooxazolo[4,5-c]pyridine-5(4H)-carboxylate
• CAS NO: 1354910-18-1
• Molecular Weight: 316.357
• Mol File: 1354910-18-1.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: tert-butyl 2-(4-hydroxyphenyl)-6,7-dihydrooxazolo[4,5-c]pyridine-5(4H)-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 2-(4-hydroxyphenyl)-6,7-dihydrooxazolo[4,5-c]pyridine-5(4H)-carboxylate(1354910-18-1)
• EPA Substance Registry System: tert-butyl 2-(4-hydroxyphenyl)-6,7-dihydrooxazolo[4,5-c]pyridine-5(4H)-carboxylate(1354910-18-1)

Safety Data

• Hazardous Substances Data: 1354910-18-1(Hazardous Substances Data)

Upstream product

• 796062-33-4 3-amino-4,4-diethoxy-piperidine-1-carboxylic acid tert-butyl ester 
• 150008-24-5 tert-butyl 4-(hydroxyimino)piperidine-1-carboxylate 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 27914-73-4 4-acetoxybenzoyl chloride 
• 2345-34-8 4-acetyloxy-benzoic acid 
• 99-96-7 4-hydroxy-benzoic acid 
• 1354910-36-3 2-(4-bromo-phenyl)-6,7-dihydro-4H-oxazolo[4,5-c]pyridine-5-carboxylic acid t-butyl ester 
• 885272-77-5 2-(4-bromo-phenyl)-4,5,6,7-tetrahydro-oxazolo[4,5-c]pyridine 
• 1017781-96-2 2-(4-bromo-phenyl)-5-methyl-4,5,6,7-tetrahydro-oxazolo[4,5-c]pyridine 
• 1354910-38-5 C₁₃H₁₀BrN₂O⁽¹⁺⁾*I^(1-) 
• 934331-03-0 C₁₂H₉BrN₂O₂ 
• 934331-04-1 2-(4-bromophenyl)[1,3]oxazolo[4,5-c]pyridine 
• 6320-39-4 3-aminopyridin-4-ol 
• 586-75-4 4-chlorobenzoyl chloride 

Downstream Products

• 1354910-19-2 2-[4-(4-trifluoromethyl-benzyloxy)-phenyl]-6,7-dihydro-4H-oxazolo[4,5-c]pyridine-5-carboxylic acid t-butyl ester 
• 1354910-40-9 2-[4-(4-trifluoromethyl-benzyloxy)-phenyl]-6,7-dihydro-4H-oxazolo[4,5-c]pyridine 

Relevant articles and documents

PROCESSES FOR PREPARING AN S1P-RECEPTOR MODULATOR

This application relates to processes for preparing an S1P-receptor modulator "Compound 1", which is useful in the treatment of diseases or disorders associated with activity of S1P, including CNS disorders. The process comprises reacting "compound 2" with "compound 3" in the presence of a reducing agent.